Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Terbinafine
Drug ID BADD_D02160
Description Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues.[A1279] Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epoxidase), an enzyme that is part of the fungal cell wall synthesis pathway.[A1279,A1281,L9068] Terbinafine hydrochloride was granted FDA approval on 30 December 1992.[L9064]
Indications and Usage For the treatment of dermatophyte infections of the toenail or fingernail caused by susceptible fungi. Also for the treatment of tinea capitis (scalp ringworm) and tinea corporis (body ringworm) or tinea cruris (jock itch).
Marketing Status OTC; Discontinued; Prescription
ATC Code D01AE15; D01BA02
DrugBank ID DB00857
KEGG ID D02375
MeSH ID D000077291
PubChem ID 1549008
TTD Drug ID D01AYJ
NDC Product Code 72189-243; 63187-213; 69097-859; 59349-0008; 70518-1191; 76282-209; 62135-572; 71335-1668; 71205-152
Synonyms Terbinafine | Terbinafine, (Z)-isomer | Terbinafine, (Z)- | Lamisil | (E)-N-(6,6-Dimethyl-2-heptenynyl)-N-methyl-1-naphthalenementhamin hydrochloride | TDT-067 | TDT 067 | TDT067 | DA 5505 | SF 86-327 | SF 86 327 | SF 86327 | SF-86-327 | SF86327 | Terbinafine Hydrochloride
Chemical Information
Molecular Formula C21H25N
CAS Registry Number 91161-71-6
SMILES CC(C)(C)C#CC=CCN(C)CC1=CC=CC2=CC=CC=C21
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Atrial fibrillation02.03.03.002--
Back pain15.03.04.005--
Benign breast neoplasm21.05.01.009; 16.14.01.0050.001058%Not Available
Blindness17.17.01.003; 06.02.02.0010.000706%Not Available
Blister23.03.01.001; 12.01.06.0020.004233%Not Available
Blood albumin decreased13.09.01.0010.000706%Not Available
Blood bilirubin increased13.03.01.0080.002117%
Blood creatine phosphokinase increased13.04.01.0010.002822%
Blood creatinine increased13.13.01.0040.001411%
Blood pressure increased13.14.03.0050.001764%Not Available
Blood triglycerides increased13.12.03.0010.000706%Not Available
Body temperature increased13.15.01.0010.001411%Not Available
Breast tenderness21.05.05.0040.001058%Not Available
Burning sensation17.02.06.001; 08.01.09.0290.002822%Not Available
C-reactive protein increased13.09.01.0070.002470%Not Available
Cardiac failure02.05.01.001--
Cardiac tamponade02.06.01.0010.001058%
Cheilitis23.03.03.025; 07.05.01.0010.002470%
Chest discomfort22.02.08.001; 08.01.08.019; 02.02.02.0090.001764%Not Available
Chest pain02.02.02.011; 22.02.08.003; 08.01.08.002--Not Available
Chills15.05.03.016; 08.01.09.0010.003175%
Cholestasis09.01.01.0010.005645%Not Available
Chromaturia20.02.01.0020.004233%
Cold sweat08.01.03.024; 23.02.03.0020.000706%Not Available
Colitis07.08.01.0010.001411%
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Cough22.02.03.001--
Crying17.02.05.013; 12.02.11.001; 08.01.03.005; 19.04.02.0020.000706%Not Available
Deafness04.02.01.0010.001764%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 13 Pages